Open Access Open Access  Restricted Access Subscription Access

Neuropharmacological Disorders: An Outline to the General Considerations

Umesh Kumar

Abstract


Neuropharmacology is a very crucial field of science that encompasses many aspects of the nervous system from mono neuron manipulation to throughout brain, spinal cord, and peripheral nerves. To know the basis of drug development, one must first understand how neurons communicate between one another. In recent years, extremely successful progress has been made by the pharmaceutical industry on a number of disease fronts; however, the progress made in the treatment of CNS disorders has lagged behind. Although several major advancements in neurobiology have been made in the past few decades, the complicated chemical reactions driving human consciousness are still poorly understood. Diseases of the CNS are also substantially more complicated than other diseases. These disease states, including depression, epilepsy, neurodegenerative disorders, neuropathic pain, multiple sclerosis (MS) and schizophrenia are complicated disorders affecting mood, memoryand mobility: the true essence of being.Neuropharmacology is understanding the actions of drugs on the functions of the brain, whether it be on single cells or behavior, is a multilevel, multifaceted process that begins with andbuilds upon the concept of molecular interactions. Furthermore, it is   concerned with drug induced changes in the functioning of cells in the nervous system.


Full Text:

PDF

References


Wrobel S. Science, serotonin, and sadness: the biology of antidepressants - A series for the public. Faseb Journal2007; 21 (13): 3404-17.

Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nature Neuroscience2005;8 (11): 1481-9.

Basic principles of Neuropharmacology. ARU Buffalo 1999.

Lovinger DM. Communication Networks in the Brain Neurons, Receptors, Neurotransmitters, and Alcohol. Alcohol Research & Health 2008; 31 (3): 196–214.

Dekker J, Ty M, Strichartz GR. Principles of Cellular Excitability and Electrochemical Transmission. In: Golen DE, Tashjian AH, Armstrong EJ, Armstrong AW. Principles of Pharmacology “The Pathophysiologic Basis of Drug Therapy”. Lippincott Williams and Wilkins, New Delhi. Wolters Kluwer pvt. Ltd; 2008. p.79-89.

Swazey JP. Chlorpromazine In psychiatry: A study in therapeutic innovation. Vol. 74. Cambridge:M.I.T. Press;

Carlsson A. A paradigm shift in brain research. Science. 2001 Nov 2; 294(5544):1021-4.

Snyder SH. Dopamine receptor excess and mouse madness. Neuron 2006; 49(4):484-5.

Perry EK. The cholinergic hypothesis-ten years on. Br Med Bull 1986; 42(1):63-9.

Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000;61Suppl 8:5-11; discussion 12-3.

Leppik IE. Intractable epilepsy in adults. AdvExp Med Biol 2002; 497:1-7.

Shneker BF, Fountain NB. Epilepsy. Dis Mon 2003; 49:426-78.

Solbrig MV, Koob GF. Epilepsy, CNS viral injury and dynorphin. Trends PharmacolSci 2004;25(2):98-104.

Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacolgy, 5thed. New Dehli: Published by Elsevier; 2003.p.515-63.

Katzung BG, Susan B, Trevor AJ. (Eds); Lange Basic & Clinical Pharmacology. 11thed, Tata Mcgraw-Hill edition Private Limited. New Delhi. p.548.

Anne B, Emer S, Garret A. McNamara JO. Analgesic- Antipyretic Agents, Pharmacotherapy of Anxiety, Pharmacotherapy of Epilepsies. In: Goodman and Gilmans, ‘The Pharmacological Basis of Therapeutics’. 11th ed. Sydney: McGraw-Hill. Medical Publishing Division; 2000.p.452-681.

Hensiek AK, Absalom AR. Status Epilepticus. Anaesthesia Intensive Care Med 2006; 7(4):127-9.

Behera MK, Rana KS, Kanitkar M, Adhikari KM. Status epilepticus in children. MJAFI 2005; 61(2):174-8.

Finney SJ, Hirsch NP. Status epilepticus. Current anaesthesia and critical care 2005; 16:123-31.

Pedersen ME, Vestergaard HT, Hansen SL, Bah S, Diallo D, Jager AK. Pharmacological screening of Malian medicinal plantsused against epilepsy, convulsions. J Ethnopharmacol 200; 121:472-5.

“A quasi experimental study to determine the effectiveness of progressive muscle relaxation technique on anxiety among elderly people in selected old age home at Bangalore”. Disertation by Giju Thomas. Bheemappa T. Dept. of Psychiatric Nursing Sarvodaya College of Nursing Vijayanagar, Bangalore.p.1-2.

Howland RD, Mycek MJ. Anxiolytic and Hypnotic drugs. In: ‘Lippincotts Illustrated Reviews in Pharmacology’. Published by Wolters Kluwer Pvt Ltd; 1992.p.103-14.

Barar FSK. Textbook of Pharmacology. Vol 1st, 1994. Chand Publishers, New Delhi.p.104-105.

Roberts E. Gamma-amminobutyric acid. Scholarpedia 2007;2(10):3356.

Olsen RW. GABA. Neuropsychopharmacol 2002; 5:159-68.

Olstad E. Glutamate and GABA; Major Players in Neuronal Metabolism. St. Olavs Hospital, Universitetssykehuset I Trondheim 2007; 15-17.

Ghosh M.N. “Fundamentals of Experimental Pharmacology”, Scientific Book Agency, Kolkata. 2003. p.81.

Bormann J. The ‘ABC’ of GABA receptors. Tips 2000; 21:16-19.

Vogel HG, Vogel WH. Drug Discovery and Evaluation Pharmacological Assays.2nded. New York: Springer; 2002: 390.

S.K.Kulkarni In: Handbook of Experimental Pharmacology. 3rd ed. New Delhi: Vallabhprakashan Publishers; 1999.p.117-22.

Christlieb IY, Cesarman E. Thermodynamics of Skeletal Muscle during CardiocirculatoryAssist Basic ApplMiol 1997;7(3&4):281-5.

Satoskar RS, Bhandarkar SP, Rege NN. Pharmacology and Phamacotherapeuties, 9th ed. Mumbai: Popular PrakashanPvt Ltd; 2005: p. 139-302.

Webb RC. Smooth Muscle Contraction and Relaxation. AdvPhysiolEdu 2003; 27:201-6.

Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139:267-284.

Schaible HG, Vanegas H. How do we manage chronic pain.Bailliere’s Clinical Rheumatology 2000;14(4):797-811.

Tripathi KD. Essentials of Medical Pharmacology. 6thed. New Delhi: Jaypee brothers Medical Publishers (Pvt) Ltd; 2003.p.453.


Refbacks

  • There are currently no refbacks.